Welcome to our dedicated page for Geron SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Geron Corporation filings document the regulatory record of a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing imetelstat for blood cancers. The company’s disclosures cover RYTELO product revenue, operating results, financial guidance, clinical-development updates, and risks tied to oncology drug commercialization and hematology studies.
Geron’s SEC filings also record proxy governance matters, director elections, board committee assignments, executive compensation, and stockholder voting materials. Form 8-K reports document material events including furnished earnings releases and investor materials, amendments to secured debt arrangements, Nasdaq-listed common stock information, workforce restructuring and exit-cost disclosures, and board or executive officer changes.
Geron Corporation reported that stockholders approved an amendment and restatement of its 2018 Equity Incentive Plan, increasing the number of common shares issuable under the plan by 4,500,000 shares. The amendment had been previously adopted by the board of directors, subject to stockholder approval.
At the 2026 Annual Meeting, held virtually, stockholders elected director nominees including Susan M. Molineaux, Patricia S. Andrews and Constantine Chinoporos. Stockholders also approved additional proposals, including an advisory vote on executive compensation and the ratification of the independent registered public accounting firm, based on the vote totals disclosed.
Geron Corp director Robert J. Spiegel was granted a stock option for 220,000 shares of common stock. The option has an exercise price of $1.26 per share and expires on May 19, 2036.
The option will vest and become exercisable for 100% of the shares on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, as long as Spiegel remains in continuous service with Geron through that date.
GERON CORP director Elizabeth G. O'Farrell received a grant of stock options covering 220,000 shares of common stock. The options have an exercise price of $1.26 per share and expire on May 19, 2036. They vest 100% on the earlier of the next annual stockholder meeting or the first anniversary of the grant date, subject to her continuous service with the company. After this grant, she holds 220,000 options directly.
Geron Corp director Susan Molineaux received a compensation grant of stock options covering 220,000 shares of common stock at an exercise price of $1.26 per share. The option vests in full on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, contingent on her continuous service. Any unexercised portion expires on May 19, 2036. This is an equity award, not an open-market stock purchase or sale.
Geron Corp director John F. McDonald received a grant of 220,000 stock options to buy Geron common stock. The options have an exercise price of $1.26 per share and expire on May 19, 2036, providing long-term equity-based compensation.
According to the terms, the option will vest and become exercisable for all 220,000 underlying shares on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, as long as McDonald continues to serve the company through that date. There were 220,000 derivative securities held after this grant, and the filing shows no open-market buying or selling.
Geron Corp director Dawn Carter Bir received a new stock option grant. On 2026-05-20, she was awarded options to acquire 220,000 shares of Geron common stock at an exercise price of $1.2600 per share, with no cost for the grant itself.
The option covers 220,000 underlying common shares and expires on 2036-05-19. According to the terms, it will vest and become exercisable in full on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, provided she maintains continuous service with Geron through that date.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin filed an Amendment No. 3 Schedule 13G/A reporting beneficial ownership of 31,720,278 shares of Geron Corp common stock, representing 4.95% of the class. The filing states shared voting and shared dispositive power over those 31,720,278 shares and cites 640,544,661 shares outstanding as of February 20, 2026. The cover identifies Deep Track Capital, LP as the relevant entity for which Mr. Kroin may be considered a control person. The filing is signed and dated May 15, 2026.
Geron Corporation reports Soleus Capital Master Fund, L.P. and affiliated filing of 41,508,659 shares of Common Stock. The filing states these shares represent 6.5% of the class, using 641,520,974 shares outstanding as of May 1, 2026. The ownership is reported as shared voting and dispositive power across Soleus entities and Guy Levy.
Geron Corp reported that EVP and Chief Legal Officer Timothy Williams received a grant of stock options. He was awarded options to buy 2,500,000 shares of Geron common stock at an exercise price of $1.73 per share, expiring on April 12, 2036.
According to the vesting terms, 312,500 shares underlying the option will vest on October 13, 2026, with the remaining shares vesting in equal installments over the following 42 months, assuming he continues serving the company on each vesting date. This is a compensation-related award rather than an open-market purchase or sale.